27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity. 5 key findings →
Participants: 3,370 Evidence: high
Full summary, score breakdown and related studies → Original source
Comparable modest reductions in agitation occurred in patients receiving haloperidol, trazodone, BMT, and placebo. 4 key findings →
Participants: 149 Evidence: high
Full summary, score breakdown and related studies → Original source
A low-dose regimen of prednisone is not useful in the treatment of AD. 3 key findings →
Participants: 138 Evidence: high
Full summary, score breakdown and related studies → Original source
Patients taking rivastigmine were significantly less apathetic and anxious, and had fewer delusions and hallucinations while on treatment than controls. 4 key findings →
Participants: 120 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
At 6 months, galantamine significantly improved cognition and global function. 2 key findings →
Design: open-label trial Participants: 636 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Although conclusions are limited by small sample size and the possibility of a type II error, results suggest that short-term estrogen therapy does not improve symptoms of most women with AD. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Incidence rates for AD in the BLSA are consistent with published rates in other studies. 2 key findings →
Design: longitudinal study Participants: 1,236 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Studies of automobile accident frequency among drivers with AD have yielded conflicting results about the risk of accidents. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
It was difficult for a palliative care research team to influence the care of advanced dementia patients in the acute hospital setting. 3 key findings →
Design: randomized controlled trial Participants: 99 Evidence: high
Full summary, score breakdown and related studies → Original source
The of establishing the diagnosis of pneumonia and cause is with the antibiotic studies for of community-acquired studies for of community-acquired The diagnosis of is based on a of clinical and laboratory The diagnosis of is and and as well as disease, congestive heart failure, with pneumonia and cases of and are of do not require and are the of antibiotic antimicrobial is usually for and a chest radiography is usually to establish the diagnosis of examination to or is for detecting pneumonia Chest radiography is considered is for the etiologic the and or conditions. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The APOE*E4 allele of the gene for apolipoprotein E (APOE) has been reported as a risk factor for Alzheimer disease (AD) to varying degrees in different ethnic groups. 1 key finding →
Design: cohort study Participants: 4,450 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The study encompassed 284 cases with dementia and 1080 controls. 1 key finding →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Estrogen replacement therapy for 1 year did not slow disease progression nor did it improve global, cognitive, or functional outcomes in women with mild to moderate AD. 3 key findings →
Participants: 42 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Patients with Alzheimer disease (AD) commonly exhibit psychosis and behavioral disturbances that impair patient functioning, create caregiver distress, and lead to institutionalization. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Failure to consider vascular cognitive impairment without dementia underestimates the prevalence of impairment and the risk for adverse outcomes associated with vascular cognitive impairment. 3 key findings →
Design: cohort study Participants: 9,008 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This multicentre, open-label study evaluated the long-term efficacy and safety of donepezil in the treatment of patients with mild to moderately severe Alzheimer's disease (AD). 4 key findings →
Design: open-label trial Participants: 133 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The Honolulu-Asia Aging Study is a longitudinal study of Japanese-American men living in Hawaii. 4 key findings →
Design: longitudinal study Participants: 47 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Scores for periventricular hyperintensities in this sample included all possible degrees of severity, but no participant scored more than 75% of maximum for deep white-matter hyperintensities. 3 key findings →
Design: longitudinal study Participants: 698 Evidence: moderate
Full summary, score breakdown and related studies → Original source
DeFronzo Metrics Cited ByDiscovery of α-Glucosidase Inhibitors from Marine Microorganisms: Optimization of Culture Conditions and Medium CompositionBurdock fructooligosaccharide as an α-glucosidase inhibitor and its antidiabetic effect on high-fat diet and streptozotocin-induced diabetic miceThe antioxidant and antidiabetic potentials of polyphenolic-rich extracts of Cyperus rotundus (Linn.)From Pharmacogenetics to Gene Expression: Implications for Precision Medicine in DiabetesA narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesitySynthesis, antidiabetic, antioxidant and anti-inflammatory activities of novel hydroxytriazenes based on sulpha drugsRNA-Seq Analysis of the Liver Transcriptome Reveals the Networks Regulating Treatment of Sitagliptin Phosphate plus Fuzhujiangtang Granule in the Zucker Diabetic Fatty RatsEverestmab, a novel long-acting GLP-1/anti GLP-1R nanobody fusion protein, exerts potent anti-diabetic effectsSPION‐Decorated Exosome Delivered BAY55‐9837 Targeting the Pancreas through Magnetism to Improve the Blood GLC ResponseA novel self-sufficient biocatalyst based on transaminase and pyridoxal 5′-phosphate covalent co-immobilization and its application in continuous biosynthesis of sitagliptinShared Pathological Mechanisms Between Diabetes Mellitus and Neurodegenerative DiseasesEffects of Lifestyle Modification and Anti-diabetic Medicine on Prediabetes Progress: A Systematic Review and Meta-AnalysisGlibenclamide Reduces Primary Human Monocyte Functions Against Tuberculosis Infection by Enhancing M2 PolarizationNaringin enhances reverse cholesterol transport in high fat/low streptozocin induced diabetic ratsA novel strategy to prepare the precursor peptide of liraglutideImpact of metformin on patients with advanced head and neck cancer undergoing concurrent chemoradiotherapyEffects of Different Doses of Metformin on Serum Fatty Acid Composition in Type 2 Diabetic RatsInsulin resistance and cognitive performance in type 2 diabetes — The Maastricht studyDesign and synthesis of novel thiazolidine-2,4-diones as hypoglycemic agentsMetformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical TrialMetformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysisGlibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infectionNa + /H
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Alzheimer's disease sufferers have been found to have a lack of the enzyme responsible for converting choline into acetylcholine within the brain. 5 key findings →
Design: randomized controlled trial Participants: 265 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The study confirmed some previously reported risk factors but also suggested new ones. 3 key findings →
Design: case-control study Participants: 8,623 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
As galantamine slowed the decline of functional ability as well as cognition, its effects are likely to be clinically relevant. 1 key finding →
Participants: 653 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Knowledge of the relationship between various clinical characteristics and cognitive functioning is advancing, but little is known about the cognitive response to treatment for geriatric depression. 4 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this study, patients with advanced dementia and hip fracture or pneumonia had a very poor prognosis. 3 key findings →
Design: cohort study Participants: 59 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. 1 key finding →
Design: open-label trial Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →